The 8th and 2nd immuno-anticancer drug with CTLA-4 inhibitory mechanism has appeared in Korea. After more than 10 years of development, AstraZeneca created the first immuno-oncology + immuno-oncology combination option in liver cancer. According to the pharmaceutical industry on the 26th, the Ministry of Food and Drug Safety recently granted product approval to AstraZeneca's CTLA-4 immunotherapy Imjudo. Imjudo is used in combination with AstraZeneca's Imfinzi as the first-line treatment for adult patients with advanced or unresectable hepatocellular carcinoma (liver cancer).

Imjudo is the 8th licensed immuno-oncology drug in Korea. Since BMS Yervoy was approved as the first immuno-oncology drug in Decem